Krisan Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.60 M
- Paid Up Capital ₹ 0.60 M
- Company Age 15 Year, 11 Months
- Last Filing with ROC 31 Mar 2011
- Open Charges ₹ 1.50 M
About Krisan Pharmaceuticals
Krisan Pharmaceuticals Private Limited (KPPL) is a Private Limited Indian Non-Government Company incorporated in India on 23 March 2009 and has a history of 15 years and 11 months. Its registered office is in Chennai, Tamil Nadu, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2011. It's a company limited by shares with an authorized capital of Rs 0.60 M and a paid-up capital of Rs 0.60 M.
The company currently has active open charges totaling ₹1.50 M.
Leelavathy Sundaresan and Sankarasubramanian Avudanayagam serve as directors at the Company.
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24230TN2009PTC071073
- Company No.
071073
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Mar 2009
- Date of AGM
28 Sep 2011
- Date of Balance Sheet
31 Mar 2011
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Krisan Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Leelavathy Sundaresan  | Director | 23-Mar-2009 | Current |
| Sankarasubramanian Avudanayagam | Director | 23-Mar-2009 | Current |
Financial Performance of Krisan Pharmaceuticals.
Enhance accessibility to Krisan Pharmaceuticals's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Krisan Pharmaceuticals?
Unlock access to Krisan Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹1.50 M
₹0
Charges Breakdown by Lending Institutions
- City Union Bank Limited K K Nagar : 0.15 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 28 Jan 2010 | City Union Bank Limited K K Nagar | ₹1.50 M | Open |
How Many Employees Work at Krisan Pharmaceuticals?
Krisan Pharmaceuticals has a workforce of 0 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Krisan Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Krisan Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.